NRSNW — NeuroSense Therapeutics Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1875091 ·
Last close
$0.10
Market Cap
—
52W High
$0.21
52W Low
$0.10
ADV30
53
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 1,028,000 | 166,000 | 2,588,000 |
| Jun 2025 | — | — | — | — | 1,684,000 | 666,000 | 2,203,000 |
| Dec 2024 | 0 | — | -1,771,000 | -1,801,000 | 4,575,000 | 3,378,000 | 1,992,000 |
| Sep 2024 | 0 | — | -2,107,000 | -2,148,000 | 984,000 | 344,000 | 3,802,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-47,785,000
Inventory
—
Receivables
$33,000
ST Investments
—
EBIT TTM
$-3,878,000
Pretax Income TTM
$-3,949,000
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,085,000 | -11,125,000 | 1,028,000 | 2,588,000 | — | -7,671,000 |
| Dec 2024 | 0 | -9,902,000 | -10,210,000 | 4,575,000 | 1,992,000 | — | -10,135,000 |
| Dec 2023 | 0 | -12,049,000 | -10,107,000 | 3,185,000 | 4,944,000 | — | -8,354,000 |
| Dec 2022 | 0 | -10,554,000 | -10,492,000 | 7,710,000 | 2,091,000 | — | -7,616,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.08T | $1210.02 | — |
| JNJ | JOHNSON & JOHNSON | $639.90B | $265.53 | — |
| ABBV | AbbVie Inc. | $465.20B | $263.30 | — |
| MRK | Merck & Co., Inc. | $321.97B | $130.36 | — |
| NVS | NOVARTIS AG | $301.89B | $158.83 | — |
News headlines (Yahoo Finance, 1h cache)
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
2026-07-22 12:30 · Yahoo
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
2026-06-29 13:30 · Yahoo
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
2026-06-25 13:20 · Yahoo
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
2026-06-09 13:00 · Yahoo
NeuroSense Announces Pricing of Insider-Led PIPE Financing
2026-04-28 18:30 · Yahoo
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
2026-04-06 13:20 · Yahoo
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
2026-04-03 14:02 · Yahoo
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2026-03-31 13:20 · Yahoo
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
2026-03-24 13:00 · Yahoo
/C O R R E C T I O N -- NeuroSense/
2026-03-18 14:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.